ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Late-Breaking 2021"

  • Abstract Number: L01 • ACR Convergence 2021

    Immunogenicity of mRNA COVID-19 Vaccines at 4 and 12 Weeks Post Full Vaccination in Patients with Inflammatory Rheumatic Diseases

    Catherine Raptis1, Diego Andrey2, Christoph Berger3, Axel Finckh2, Pierre Lescuyer2, Adrian Ciurea4, Tanja Maletic1, Christos Polysopoulos1, Myriam Riek1, Almut Scherer1, Kim Lauper2, Burkhard Moeller5, Judith Safford6, Sandra Schweizer7, Isabell von Loga1, Nicolas Vuilleumier8 and Andrea Rubbert-Roth9, 1SCQM Foundation, Zurich, Switzerland, 2Geneva University Hospital, Geneva, Switzerland, 3University Hospital Basel, Basel, Switzerland, 4University Hospital Zurich, Zrich, Switzerland, 5Inselspital - University Hospital Bern, Bern, Switzerland, 6RheumaCura Foundation, Zurich, Switzerland, 7Swiss League Against Rheumatism, Zurich, Switzerland, 8University Hospital of Geneva, Geneva, Switzerland, 9Kantonspital St Gallen, St.Gallen, Switzerland

    Background/Purpose: Emerging evidence indicates that immunosuppressive therapies may result in reduced immunogenicity –and presumably reduced efficacy-  following vaccination with mRNA COVID-19 vaccines but long-term data…
  • Abstract Number: L17 • ACR Convergence 2021

    Additional Heterologous versus Homologous Booster Vaccination in Immunosuppressed Patients Without SARS-CoV-2 Antibody Seroconversion After Primary mRNA Vaccination: A Randomized Controlled Trial

    Michael Bonelli1, Daniel Mrak1, Selma Tobudic1, Daniela sieghart1, Peter Mandl1, barbara kornek1, elisabeth simader1, Maximilian Koblischke1, Helga Radner1, thomas perkmann1, helmuth haslacher1, Margareta Mayer1, philipp hofer1, Kurt Redlich2, Emma Husar-Memmer3, Ruth Fritsch-Stork4, Renate Thalhammer1, Karin Stiasny1, Stefan Winkler1, Josef Smolen1, Judith Aberle1, Markus Zeitlinger1, Leonhard Heinz1 and Daniel Aletaha5, 1Medical University of Vienna, Vienna, Austria, 2Hietzing Hospital, Vienna, Austria, 3Hanusch Hospital, Vienna, Austria, 4Sigmund Freud University, Utrecht, Netherlands, 5Medical University Vienna, Wien, Austria

    Background/Purpose: Severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)-induced coronavirus disease 2019 (COVID-19) has led to exponentially rising mortality, particularly in immunosuppressed patients, who inadequately respond to…
  • Abstract Number: L02 • ACR Convergence 2021

    COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune Diseases

    Ines Colmegna1, Mariana Useche1, Emmanouil Rampakakis2, Nathalie Amiable3, Emmanuelle Rollet-Labelle3, Louis Bessette4, Jo-Anne Costa4, Marc Dionne4, Mary-Ann Fitzcharles2, Elizabeth Hazel2, Deirdre McCormack2, Laetitia Michou4, Pantelis Panopalis2, Marc-Andre Langlois5, Sasha Bernatsky6 and Paul R. Fortin7, 1The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 2McGill University Health Centre, Montreal, QC, Canada, 3Centre de Recherche du CHU de Quebec, Quebec, Canada, 4Universite Laval, Quebec, QC, Canada, 5University of Ottawa, Ottawa, ON, Canada, 6McGill University, Montreal, QC, Canada, 7CHU de Quebec - Universite Laval, Quebec, Canada

    Background/Purpose: Immunocompromised conditions and/or a history of autoimmune disease were exclusion criteria of the initial SARS-CoV-2 vaccines clinical trials. We assessed the safety and immunogenicity…
  • Abstract Number: L18 • ACR Convergence 2021

    Humoral and Cellular Immune Responses to a Second Dose of COVID-19 Vaccine BNT162b2 in People Receiving Methotrexate or Targeted Immunosuppression: A Cohort Study

    Satveer K Mahil1, Katie Bechman2, Antony Raharja1, Clara Domingo-Vila3, David Baudry1, Matt Brown2, Andrew Cope2, Tejus Dasandi1, Hataf Khan4, Thomas Lechmere4, Michael Malim4, Freya Meynell1, Emily Pollock3, Kamila Sychowska3, Jonathan Barker1, Sam Norton5, James Galloway2, Katie Doores4, Timothy Tree3 and Catherine Smith1, 1St John’s Institute of Dermatology, Guy’s and St Thomas’ NHS Foundation Trust and King’s College London, London, 2Centre for Rheumatic Diseases, King's College London, London, 3Department of Immunobiology, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom, 4Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, United Kingdom, 5Psychology Department, Institute for Psychiatry Psychology & Neuroscience, King’s College London, London

    Background/Purpose: COVID-19 vaccines have robust immunogenicity in the general population. Data on individuals with immune-mediated inflammatory diseases who are taking immunosuppressants remains limited. Our cohort…
  • Abstract Number: L03 • ACR Convergence 2021

    COVID-19 Vaccine Antibody Responses in Patients Treated with B-Cell Agents Depend on B-Cell Counts at Time of Vaccine

    Kyriakos Kirou and Jeffrey Zhang-Sun, Hospital for Special Surgery, New York, NY

    Background/Purpose: Optimal COVID-19 vaccine responses are necessary to protect against severe infection. Patients with systemic rheumatic diseases (SRD) are at risk for not mounting adequate…
  • Abstract Number: L19 • ACR Convergence 2021

    Secukinumab in Giant Cell Arteritis: A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase 2 Trial

    Nils Venhoff1, Wolfgang Schmidt2, Raoul Bergner3, Jürgen Rech4, Leonore Unger5, Hans-Peter Tony6, Meryl Mendelson7, Christian Sieder8, Meron Maricos8 and Jens Thiel9, 1Department of Rheumatology and Clinical Immunology, Vasculitis Center Freiburg, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany, 2Immanuel Krankenhaus Berlin, Medical Center for Rheumatology Berlin-Buch, Lindenberger Weg 19, 13125 Berlin, Germany, Berlin, Germany, 3Medizinische Klinik A, Klinikum der Stadt Ludwigshafen, Ludwigshafen, Germany, 4Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054,, Erlangen, Germany, 5Medical Department 1, Städtisches Klinikum Dresden, Dresden, Germany, 6Department of Medicine 2, Rheumatology and Clinical Immunology Oberduerrbachertstr. 697080, Wuerzburg, Germany, 7Novartis Pharmaceuticals Corporation, East Hanover, NJ, 8Novartis Pharma GmbH, Nuremberg, Germany, 9Department of Rheumatology and Clinical Immunology, Vasculitis Center Freiburg, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany; Division of Rheumatology and Immunology, Department of Internal Medicine, Medical University of Graz, Graz, Austria

    Background/Purpose: Little is known about glucocorticoid-sparing agents in giant cell arteritis (GCA) except for IL-6 inhibition. Secukinumab (SEC) has shown significant improvements in the signs…
  • Abstract Number: L04 • ACR Convergence 2021

    SARS-CoV-2 Infections Among Vaccinated Individuals with Rheumatic Disease: Results from the COVID-19 Global Rheumatology Alliance Provider Registry

    Jean Liew1, milena Gianfrancesco2, Carly Harrison3, zara Izadi2, Stephanie Rush2, Lindsay Jacobsohn2, Clairissa Ja2, Saskia Lawson-Tovey4, Kimme Hyrich5, Laure Gossec6, Anja Strangfeld7, Loreto Carmona8, Martin Schaefer7, ELSA MATEUS9, Samar Al Emadi10, Claire Cook11, Fatemah Abutiban12, Dfiza Dey13, Emily Kowalski14, Marco Martinez-Martinez15, Naomi Patel11, Evelyn Salido16, Jeffrey Sparks17, leanna Wise18, Suleman Bhana19, Wendy Costello20, Rebecca Grainger21, Jonathan Hausmann22, Emily Sirotich23, Paul Sufka24, Zachary Wallace25, Pedro Machado26, Philip Robinson27 and Jinoos Yazdany2, 1Boston University School of Medicine, Boston, MA, 2University of California San Francisco, San Francisco, CA, 3Lupus Chat, New York, NY, 4Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, University of Manchester, National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, 5Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester Academic Health Science Centre, National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, 6INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, Sorbonne Universite, Paris, France APHP, Rheumatology Department, Hopital Universitaire Pitie Salpetriere, Paris, France, Paris, France, 7German Rheumatism Research Center (DRFZ Berlin), Epidemiology and Health Care Research, Berlin, Germany, 8Instituto de Salud Musculoesquelética, Madrid, Spain, 9EULAR, Lisboa, Portugal, 10Hamad Medical Corporation, Doha, Qatar, 11Massachusetts General Hospital, Boston, MA, 12Rheumatology Unit, Department of Medicine, Jaber Alahmed Alsabah Hospital, KUWAIT, Kuwait, 13Rheumatology Unit , Department of Medicine and Therapeutics, University of Ghana Medical School, Korle Bu Teaching Hospital, Accra, Ghana, 14Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 15Instituto Mexicano del Seguro Social, San Luis Potosí, Mexico, 16University of the Philippines Manila, Manila, Philippines, 17Brigham and Women's Hospital, Boston, MA, 18University of Southern California, Los Angeles, CA, 19Pfizer, Montvale, NJ, 20Irish Children's Arthritis Network (iCAN), Bansha, Ireland, 21University of Otago, Wellington, New Zealand, 22Boston Childrens Hospital, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 23McMaster University, Hamilton, ON, Canada, 24HealthPartners, Eagan, MN, 25Massachusetts General Hospital, Harvard Medical School, Boston, MA, 26Centre for Rheumatology & Department of Neuromuscular Diseases, University College London; National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre, University College London Hospitals NHS Foundation Trust; Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, London, United Kingdom, 27University of Queensland School of Clinical Medicine, Herston, Queensland; Department of Rheumatology, Royal Brisbane and Women’s Hospital, Metro North Hospital and Health Service, Queensland, Australia., Brisbane, Australia

    Background/Purpose: While COVID-19 vaccinations are a critical tool to prevent severe infections, poor immunogenicity in immunocompromised people threatens vaccine effectiveness. We analyzed clinical characteristics of…
  • Abstract Number: L20 • ACR Convergence 2021

    Efficacy of Emapalumab, an Anti-IFNγ Antibody in Patients with Macrophage Activation Syndrome (MAS) Complicating Systemic Juvenile Idiopathic Arthritis (sJIA) Who Had Failed High-Dose Glucocorticoids (GCs)

    Fabrizio De Benedetti1, Alexei Grom2, Paul Brogan3, Claudia Bracaglia1, Manuela Pardeo1, Giulia Marucci1, Despina Eleftheriou3, Charalampia Papadopoulou3, Pierre Quartier4, Jordi Antón5, Rikke Frederiksen6, Veronica Asnaghi6 and Cristina De Min6, 1Bambino Gesù Children's Hospital IRCCS, Rome, Italy, 2Cincinnati Children’s Hospital, Division of Rheumatology, Cincinnati, OH, 3UCL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, 4Université de Paris, IMAGINE Institute, RAISE reference centre, Pediatric Immuno-Hematology and Rheumatology Unit, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France, 5Hospital Sant Joan de Déu, Division of Pediatric Rheumatology, University of Barcelona, Barcelona, Spain, 6Swedish Orphan Biovitrum AG (Sobi), Basel, Switzerland

    Background/Purpose: MAS is a life-threatening complication of rheumatic diseases, occurring most frequently in sJIA. The mainstay of MAS treatment is high dose GCs; however, GCs…
  • Abstract Number: L05 • ACR Convergence 2021

    Phase 2 Study Results from a Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate Efficacy and Safety of Tigulixostat, a Novel Non-purine Selective Xanthine Oxidase Inhibitor, in Gout Patients with Hyperuricemia

    Robert Terkeltaub1, JuneSik Mune2, Jieun Lee3 and Kenneth Saag4, 1VA/UCSD, San Diego, CA, 2LG Chem, Ltd., Seoul, 3LG Chem, Ltd., Seoul, South Korea, 4The University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Gout can be effectively managed by inhibiting synthesis of uric acid. Tigulixostat is a novel non-purine selective xanthine oxidase inhibitor which lowers production of…
  • Abstract Number: L21 • ACR Convergence 2021

    Rituximab versus Conventional Therapeutic Strategy for Remission Induction in Eosinophilic Granulomatosis with Polyangiitis: A Double-blind, Randomized, Controlled Trial

    Benjamin Terrier1, Gregory Pugnet2, Claire de Moreuil3, Bernard Bonnotte4, Ygal Benhamou5, Elisabeth Diot6, Dominique Chauveau2, Pierre Duffau7, Nicolas Limal8, Antoine Neel9, Geoffrey Urbanski10, Noemie Jourde-Chiche11, Nicolas Martin-Silva12, Francois Maurier13, Arsene Mekinian14, Nicolas Schleinitz11, Felix Ackermann15, Anne-Laure Fauchais16, Antoine Froissart17, Thomas Le Gallou18, Yurdagul Uzunhan19, Jean-Francois Viallard7, Alice Berezne20, Laurent Chiche21, Bruno Crestani14, Guillaume Direz22, Cecile-Audrey Durel23, Pascal Godmer24, Jean-Emmanuel Kahn25, Marc Lambert26, Thomas Quemeneur27, Jacques Cadranel14, Pierre Charles28, Antoine Dossier14, Lea Jilet29, Loic Guillevin14, Hendy Abdoul29 and Xavier Puechal14, 1Cochin Hospital, Paris, France, 2CHU, Toulouse, France, 3CHU, Brest, France, 4CHU, Dijon, France, 5CHU, Rouen, France, 6CHU, Tours, France, 7CHU, Bordeaux, France, 8CHU, Creteil, France, 9CHU, Nantes, France, 10CHU, Angers, France, 11CHU, Marseille, France, 12CHU, Caen, France, 13CH, Metz, France, 14CHU, Paris, France, 15Hopital Foch, Suresnes, France, 16CHU, Limoges, France, 17CHIC, Creteil, France, 18CHU, Rennes, France, 19CHU, Bobigny, France, 20CH, Annecy, France, 21CH, Marseille, France, 22CH, Le Mans, France, 23CHU, Lyon, France, 24CH, Vannes, France, 25CHU, Boulogne, France, 26CHRU, Lille, France, 27CH, Valenciennes, France, 28CH, Paris, France, 29URC, Paris, France

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is an eosinophilic ANCA-associated vasculitis.Glucocorticoids, alone or in combination with cyclophosphamide in severe forms, induce remission in most patients…
  • Abstract Number: L06 • ACR Convergence 2021

    Comparative Safety of Gout “Treat-to-target” and “Usual Care” Treatment Strategies on Cardiovascular Outcomes Using Observational Data: Causal Inference Approach

    Kazuki Yoshida, Jun Liu, Daniel Solomon, Robert J Glynn and Seoyoung Kim, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Rheumatology societies recommend serum-urate (SU)-driven treat-to-target (TTT) strategies for the management of gout. However, cardiovascular (CV) safety of urate-lowering therapy (ULT) has been questioned.…
  • Abstract Number: L07 • ACR Convergence 2021

    Depletion of KLRG1+ T Cells in a First-in-human Clinical Trial of ABC008 in Inclusion Body Myositis (IBM)

    Niti Goel1, Dulce Soler-Ferran2, Monette Coutreau2, Jorge Escobar3, Kate Courtemanche2, Merrilee Needham4 and Steven Greenberg5, 1Abcuro, Inc.; Duke University, Durham, NC, 2Abcuro, Inc., Newton, MA, 3Abcuro, Inc., Hayward, CA, 4Perron Institute, Murdoch University, Perth, Australia, 5Brigham and Women's Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Inclusion body myositis (IBM), a relentlessly progressive autoimmune skeletal muscle disease, has no effective available pharmacological therapy. A prominent feature of IBM on microscopy…
  • Abstract Number: L08 • ACR Convergence 2021

    Association of Limited Health Literacy with Clinical and Patient-Reported Outcomes in Systemic Lupus Erythematosus: An Analysis from the Peer Approaches to Lupus Self-Management (PALS) Program

    Mithu Maheswaranathan1, Andrea Boan2, Viswanathan Ramakrishnan2, Hetlena Johnson3, Jillian Rose-Smith4, Clara Dismuke-Greer5, Leonard Egede6, Jim Oates2 and Edith Williams2, 1Duke University, Durham, NC, 2Medical University of South Carolina, Charleston, SC, 3LupusCSC, Columbia, SC, 4Hospital for Special Surgery, New York, NY, 5VA Palo Alto, Palo Alto, CA, 6Medical College of Wisconsin, Milwaukee, WI

    Background/Purpose: Health literacy (HL) is an important social determinant of health defined as the ability to understand and use health information.  Limited HL is associated…
  • Abstract Number: L09 • ACR Convergence 2021

    A Prediction Model to Distinguish Patients with Multisystem Inflammatory Syndrome in Children

    Matthew Clark1, Danielle Rankin2, Alisa Gotte1, Alison Herndon1, William McEachern1, Andrew Smith3, Daniel Clark1, Edward Hardison1, Anna Patrick1, Lauren Peetluk1, Natasha Halasa1, James Connelly1 and Sophie Katz1, 1Vanderbilt University Medical Center, Nashville, TN, 2Vanderbilt University, Nashville, TN, 3The Heart Institute, Johns Hopkins All Children's Hospital, St. Petersburg, FL

    Background/Purpose: Multisystem inflammatory syndrome in children (MIS-C) is a rare consequence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). MIS-C shares features with common infectious and…
  • Abstract Number: L10 • ACR Convergence 2021

    A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease

    joshua solomon1, Felix Woodhead2, Sonye Danoff3, Shana Haynes-Harp4, Tanvi Naik5, Cathie Spino5, Shelley Hurwitz6, Rie Maurer6, Daniel Chambers7, Martin Kolb8, Hiliary Goldberg6 and Ivan Rosas4, 1National Jewish Health, Denver, CO, 2University of Leicester, Leicester, United Kingdom, 3Johns Hopkins University, Baltimore, MD, 4Baylor College of Medicine, Houston, TX, 5University of Michigan, Ann Arbor, MI, 6Brigham and Womens Hospital, Boston, MA, 7University of Queensland, Brisbane, Australia, 8McMaster University, Hamilton, ON, Canada

    Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a prevalent and morbid condition leading to premature death in 10% of those affected. The TRAIL1 trial…
  • 1
  • 2
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology